

## Products renewal-

# Article 43 of Regulation (EC) No 1107/2009

CEUREG FORUM XIX, 5 -6<sup>th</sup> November 2015

**Rebecca Reboul**

Institute for Plant Protection Products

AGES, Austrian Agency for Health and Food Safety

# Outline

- 1. **Article 43- General considerations**
- 2. **Renewal procedures**
- 3. **Mixed products (> 1 a.s)**
- 4. **Outlook**



**Before**



**After  
renewal**



# 1- Article 43- General considerations

## Renewal of PPP Art. 43, GD SANCO/2010/13170 rev. 13

- **application for renewal of PPP** - **3 months** after Commission's decision („date of application“ DoA) of renewal of the a.s
- **evaluation** [compliance check + assessment ] and **decision** on renewal of the PPP by **zRMS** - **6 months** (including Peer review: 3 w.)
- **decision** on renewal of authorisations by **cMS** - **3 months**

!!! Applications by ALL authorisation holders!!!  
(notifying and non-notifying companies)

No application for renewal within 3 months or incomplete submissions : expiry of the authorisations or they will be revoked according to Art. 44 (3) and (4)



© Ron Leishman \* www.ClipartOf.com/443177

# 1- Article 43- General considerations



## Preconditions for application according to Art. 43:

- **no new uses!**
- **GAPs remain unchanged** (what if the GAP has to be changed because of new end-points?)
- **no formulation change!** (except: non-significant change according to GD SANCO/12638/2011)
- **no new cMS** (for which the product is new)!

If preconditions are not fulfilled

-> considered as a new PPP according to Art. 33

-> new uses to be applied for after the renewal of the PPP, as an amendment according to Art. 33 or Art. 40

# 1- Article 43- General considerations

## Challenges

- **short timelines** (for applicant as well as for MS)
- high number of PPP within a zone,  
high number of PPP with more than one a.s.
- new endpoints for the a.s. ...

## HOWEVER... Possibility to extend timelines:

- Art. 43 (6): *MS should extend the authorisation for the period necessary to complete the examination*  
In which case(s) does **extension** of authorisation apply? How long?



## 2- Renewal procedures



**Application:** Some (a lot of?) dossiers will **not be complete** due to lack of time to comply with **new data requirements, new endpoints, to complete long term or seasonal studies, or capacities of laboratories!**

**Which data can be submitted later?** (SANCO/2010/13170)

### **-> Cat. 4 studies**

- studies related to new end points /time is insufficient to generate these studies (e.g. mesocosm studies, residue trials; efficacy trials if necessary because of changed end points -> lowering of amount active/ha)

**MS may grant **extension of the concerned authorisation until studies are made available****

**Cat. 1, 2, 3, 5 studies:** eg: "formal" studies which do not impact the safety of the PPP

## 2- Renewal procedures

### Application (Cat. 4 studies ongoing missing) should contain:

- all necessary studies available at the time of application
- **list of studies to be generated**, i.e. Cat. 4 studies, including time table for study submission and justification – to be accepted by the zRMS
- **complete dRR**, only once all studies are available - **max. 2 years**
  - highlighting the changes to the risk assessment
  - old dRR acceptable for AIR 2 PPPs

**-> 2 Steps application**



## 2- Renewal procedures



- **compliance check** to be performed by each MS having authorisations, **compliance with the conditions and restrictions** of the active renewal
- where relevant - applicant is non-notifier - : **data matching check** (PAI meeting, Sept 2015) to be performed by the zRMS (compensation studies, LoA or indications that studies will be provided)
- **equivalence check(s)** to be performed by the RMS for the active's renewal



## 2- Renewal procedures

### Assessment:

- assessment to be performed **by the zRMS**
- > begin of the evaluation only when dossier complete
- > only new information necessary to be considered
- based on the dRR provided by the applicant (quality...)
- „new“ consideration of the risk envelope approach for some sections like residues, fate (worst case: GAP for one PPP? other PPPs covered?)



### **Presubmission meeting !!!!**



Not to forget: **comparative assessment** (Art 50) as well as **data protection issues** to be dealt at MS level



## 2- Renewal procedures



### Risk Assessment:

- **relevant chapters** only (for which new/changed endpoints are applicable), the others will **NOT** be considered -> latest Guidance to be applied

### Efficacy:

- **no assessment of efficacy** (=no updated BAD)
- exception for „**possible development of resistance or cross-resistance**“ to be presented in a new dRR (Section 7) (OECD KIII6.2.8)
  - > if GAP has to be changed because of risk assessment issues resulting from changed endpoints (i.e. necessary to lower the application rate/ha):
  - > new efficacy trials (reflecting the new GAP) might be necessary („Cat. 4 studies“)

## 3- Mixed products(>1 a.s.)



PPPs for which the period between the renewals of two a.s. is:

### **less than 1 year:**

- > **evaluation** only after the last a.s. has been renewed
- > BUT **application** after each a.s.' renewal
- > **dRR** to be provided once the 2nd a.s. renewed

### **more than 1 year:**

- > **no need for an assessment of the additional actives in the PPP since no agreed endpoints are applicable, once the 2<sup>nd</sup> substance is renewed, there is no need to look at the 1<sup>st</sup> substance again**

## 4- Outlook



### **Member States:**

- Art 43 vs Art 33; Internal priority setting by authorities?
- strategy: comparative assessment (to be looked at asap)
- worksharing of MS (interzonal, within the zone)
- when evaluation of PPP ongoing before renewal of the a.s. and new EP are used, no article 43 necessary

### **Companies:**

- reconsideration of the PPP portfolio, apply Art.40 in advance in some MS
- notification sheets to be sent: some PPP in the central zone are still without zRMS (no preference given by the applicant)
- quality of the dRR (old dRR acceptable for AIR2 PPPs/ completeness of information at the application)

## 4- Outlook



### **Implication for Data protection**

- 30 months data protection from the renewal of the PPP (for a.s. and PPP data) - Art. 59
- if delayed submission of the complete dossier=> begin of the 30 months data protection with date of PPP renewal => max. 2y+1y evaluation

### **Situation for non-notifying companies**

- application to be made 3 months after EI of a.s. renewal
- include a list of studies, justification why couldn't be made
- extension of the expiry date of the PPP in parallel to the reference PPP (if applied for)
- authorisation revoked at the renewal of the reference PPP
- new application Art 33 (based on Art. 34) as soon as data protection ok

## 4- Outlook



### **Implication for minor uses :**

only for existing (authorised) minor uses

- when possible, e.g. authorisation holder is the data owner (residue data), evaluation to be performed by zRMS
- some cases, data owner (group of interest...) is not the authorisation holder and cannot prepare the dRR – solution has to be found at national level

**Thank you for your attention**

